Research and Markets has announced the addition of the "Anxiety Disorders - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Anxiety Disorders Overview
- Therapeutics Development
- Pipeline Products for Anxiety Disorders - Overview
- Pipeline Products for Anxiety Disorders - Comparative Analysis
- Anxiety Disorders - Therapeutics under Development by Companies
- Anxiety Disorders - Therapeutics under Investigation by Universities/Institutes
- Anxiety Disorders Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Anxiety Disorders - Products under Development by Companies
- Anxiety Disorders - Products under Investigation by Universities/Institutes
- Anxiety Disorders - Companies Involved in Therapeutics Development
- AbbVie Inc.
- Ache Laboratorios Farmaceuticos S/A
- Adamed Sp. z o.o.
- Addex Therapeutics Ltd
- Amorsa Therapeutics Inc.
- Avineuro Pharmaceuticals, Inc.
- Azevan Pharmaceuticals, Inc.
- Bionomics Limited
- Boehringer Ingelheim GmbH
- C4X Discovery Holdings PLC
- Catalyst Pharmaceutical Partners, Inc.
- Edgemont Pharmaceuticals, LLC
- Eisai Co., Ltd.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Gabather AB
- GW Pharmaceuticals Plc
- HolsboerMaschmeyer NeuroChemie GmbH
- Humanetics Corporation
- IntelGenx Corp.
- Intra-Cellular Therapies, Inc.
- INVENT Pharmaceuticals, Inc.
- Marinus Pharmaceuticals, Inc.
- Merz Pharma GmbH & Co. KgaA
- MI.TO. Technology S.r.L.
- Nemus Bioscience, Inc.
- Neuralstem, Inc.
- Neurelis, Inc.
- NeuroNascent, Inc.
- Newron Pharmaceuticals S.p.A.
- Nippon Chemiphar Co., Ltd.
- Novartis AG
For more information visit http://www.researchandmarkets.com/research/n2q36x/anxiety_disorders
View source version on businesswire.com: http://www.businesswire.com/news/home/20160429005800/en/
Contacts:
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Mental
Disorders Drugs